Improving Competitive Drug Markets by Reviewing Patents

Generic and biosimilar drugs save consumers billions of dollars and improve health by reducing cost-related barriers to access. The timely availability of these products depends on their patents, so this study will compare the effectiveness of different strategies used to review the validity of drug patents, including litigation and administrative proceedings within the US Patent and Trademark Office. Findings may help policymakers modify intellectual property protection rules to enhance the competitiveness of the US drug market.